Anacor Pharmaceuticals Inc

Find Ratings Reports
ANAC : : Health Care
$99.22 up 0.05 | 0.05%
Today's Range: 99.20 - 99.27
Avg. Daily Volume: 2,547,900
06/23/16 - 3:59 PM ET

Financial Analysis


ANACOR PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ANACOR PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 6.03 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 42.44% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)17.5415.26
EBITDA ($mil)-14.73-11.65
EBIT ($mil)-14.92-11.8
Net Income ($mil)-16.15-12.96


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)135.77175.41
Total Assets ($mil)164.0214.89
Total Debt ($mil)62.2660.81
Equity ($mil)44.6377.54


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin-84.0-76.32
EBITDA Margin-83.99-76.31
Operating Margin-85.09-77.28
Sales Turnover0.520.15
Return on Assets-39.28-36.73
Return on Equity-144.36-101.79
Debt Q1 FY16 Q1 FY15
Current Ratio6.294.58
Debt/Capital0.580.44
Interest Expense1.431.36
Interest Coverage-10.43-8.69


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)45.3743.75
Div / share0.00.0
EPS-0.36-0.3
Book value / share0.981.77
Institutional Own % n/a n/a
Avg Daily Volume2585274.0944662.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 100.83 indicates a significant premium versus the S&P 500 average of 2.79 and a significant premium versus the industry average of 10.99. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, ANACOR PHARMACEUTICALS INC proves to trade at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ANAC NM Peers 38.24   ANAC NM Peers 20.79

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

ANAC's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ANAC's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ANAC NM Peers 113.48   ANAC NA Peers 1.01

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

ANAC's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ANAC 100.83 Peers 10.99   ANAC 21.51 Peers -18.19

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ANAC is trading at a significant premium to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

ANAC is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ANAC 53.18 Peers 379.00   ANAC 166.18 Peers 42.06

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ANAC is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

ANAC has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades